Related Experiment Video
Updated: Jun 2, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Advanced Targeted Therapy for Colorectal Cancer with Lipid Nanoparticles
Pawan Kedar1, Sankha Bhattacharya1, Preeti Sakore1
1Department of Pharmaceutics, School of Pharmacy and Technology Management, Mukesh Patel Technology Park, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Abstract:
Targeted therapy for colorectal cancer (CRC) appears to have great potential with lipid nanoparticles (LNPs). The advances in LNP-based techniques, such as liposomes, exosomes, micelles, solid lipid nanoparticles (SLNs), nano-cubosomes, and plant- derived LNPs (PDLNPs), are explored in detail in this thorough review. Every platform provides distinct advantages: liposomes enable precise drug release and improved delivery; exosomes function as organic nanocarriers for focused treatment; SLNs offer greater stability; micelles enhance drug solubility and resistance; nano-cubosomes tackle low bioavailability; and PDLNPs offer biocompatible substitutes. The mechanisms, benefits, drawbacks, and therapeutic potential of these LNP platforms in the treatment of colorectal cancer are highlighted in the review. The review highlights how crucial it is to use these technologies for efficient CRC management and looks at potential future developments for them. The controlled release properties of liposomes and solid liposome nanoparticles (SLNs) improve the stability and bioavailability of medicinal compounds. On the other hand, exosomes and micelles provide answers for medication resistance and solubility issues, respectively. Novel strategies for resolving bioavailability problems and enhancing biocompatibility include nano-cubosomes and PDLNPs. These LNP-based systems are promising in clinical applications for boosting therapeutic efficacy, decreasing systemic toxicity, and facilitating tailored drug delivery. By incorporating these nanotechnologies into CRC treatment plans, present therapeutic approaches may be completely changed, and more individualized and efficient treatment choices may be provided. To completely comprehend the advantages and drawbacks of these LNP systems in therapeutic settings, as well as to and optimize them, more study is recommended by the review. Treatment for colorectal cancer may be much improved in the future thanks to developments in LNP-based drug delivery systems. These technologies hold great promise for improving patient outcomes and advancing the field of oncology by tackling important issues related to medication delivery and bioavailability.
Insights
Lipid nanoparticles (LNPs) offer promising targeted therapy for colorectal cancer (CRC). Various LNP platforms enhance drug delivery, stability, and bioavailability, potentially revolutionizing CRC treatment and improving patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Colorectal cancer (CRC) remains a significant health challenge, necessitating advanced therapeutic strategies.
- Targeted therapy holds promise for improving treatment efficacy and reducing side effects in CRC management.
- Lipid nanoparticles (LNPs) have emerged as a key technology for enhancing drug delivery in cancer treatment.
Purpose of the Study:
- To review the diverse landscape of lipid nanoparticle (LNP) platforms for colorectal cancer (CRC) targeted therapy.
- To explore the mechanisms, advantages, disadvantages, and therapeutic potential of various LNP types in CRC treatment.
- To highlight the future prospects and research directions for LNP-based CRC therapies.
Main Methods:
- Comprehensive review of existing literature on LNP applications in colorectal cancer therapy.
- Analysis of different LNP platforms including liposomes, exosomes, micelles, solid lipid nanoparticles (SLNs), nano-cubosomes, and plant-derived LNPs (PDLNPs).
- Evaluation of LNP properties such as drug release, stability, bioavailability, solubility, and biocompatibility in the context of CRC.
Main Results:
- Various LNP platforms offer distinct benefits for CRC treatment: liposomes and SLNs improve drug release and stability; exosomes facilitate targeted delivery; micelles enhance solubility; nano-cubosomes address bioavailability; and PDLNPs provide biocompatible options.
- LNP-based systems demonstrate potential for increased therapeutic efficacy, reduced systemic toxicity, and personalized drug delivery in CRC.
- Controlled release and improved bioavailability are key advantages offered by platforms like liposomes and SLNs.
Conclusions:
- Lipid nanoparticles represent a versatile and powerful tool for advancing colorectal cancer targeted therapy.
- Further research is recommended to fully understand and optimize LNP systems for clinical application in CRC.
- LNP advancements promise to significantly improve patient outcomes and transform future CRC treatment strategies.
